About ADMA Biologics
ADMA Biologics is a publicly listed company based in Ramsey (United States) founded in 2005 by Adam Grossman. Plasma-based biologics are developed for immune deficiency and infectious diseases. ADMA Biologics has raised $17.55 million across 6 funding rounds from investors including Hercules Capital, Oxford Finance and Perceptive Advisors. The company has 685 employees. Its chief executive, as recorded, is Adam Grossman. Its website admabiologics.com draws about 13 thousand monthly visits. ADMA Biologics offers products and services including ASCENIV, BIVIGAM, and Nabi-HB. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is ADMA BIOLOGICS, INC. Its competitors include Biogen, Kymeratx and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
ADMA Biologics was founded in 2005 and is headquartered in Ramsey, United States. Operations focus on the development, manufacturing, and marketing of plasma-derived immune globulins targeted at niche patient populations. These biologics address primary immune deficiency diseases and certain infectious conditions. The lead product, RI-002, completed phase 3 clinical trials, with a biologics license application submitted to the FDA in 2015.
- Headquarters Ramsey, United States
- Employees 685
- Founders Adam Grossman
- Stage Public
- SectorsHealthcare
- Website admabiologics.com
- Social LinkedIn X
- Legal Name Adma Biologics Inc
- Annual Revenue$510.17 M (USD)19.63as on Dec 31, 2025
- Net Profit$146.93 M (USD)-25.67as on Dec 31, 2025
- EBITDA$199.54 M (USD)35.71as on Dec 31, 2025
- Total Equity Funding$17.55M (USD)
in 6 rounds
- Latest Funding Round$72.5M (USD), Debt – Conventional
Feb 2019
- InvestorsHercules Capital
& 4 more
- Employee Count685
Products & Services of ADMA Biologics
ADMA Biologics offers a comprehensive portfolio of products and services, including ASCENIV, BIVIGAM, and Nabi-HB.
Treatment for primary immunodeficiency diseases.
Immune globulin product for medical applications.
Hepatitis B immune globulin for infection prevention.
Funding Insights of ADMA Biologics
ADMA Biologics has successfully raised a total of $17.55M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $72.5 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.55M
- Total Rounds 6
- Last Round Debt – Conventional — $72.5M
- First Round $17.55M
(Feb 2012)
- Investors Count 5
All 6 funding rounds of ADMA Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $72.5M | Debt – Conventional | – | – | |
| Jun 2015 | $16M | Debt – Venture | – | – | |
| Dec 2014 | $5M | Debt – Venture | – | – | |
| Feb 2014 | $15M | Debt – Venture | – | – | |
| Dec 2012 | $4M | Debt – Venture | – | – | |
| Feb 2012 | $17.55M | Private Equity Round | – | Aisling Capital, Burrill and Company | – |
5 investors in total: 5 institutional.
Investors in ADMA Biologics
ADMA Biologics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Oxford Finance and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China |
Investor details for ADMA Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ADMA Biologics
42 people are tracked at ADMA Biologics (21 in leadership, 11 in board & advisors, 10 in team); the tracked headcount is 685.
| Name | Role | Group |
|---|---|---|
Adam Grossman | Founder & CEO | Leadership |
Michael Least | Vice President, Market Access & National Accounts | Leadership |
Drew Pantello | VP, Marketing & Corporate Development | Leadership |
Michael Space | VP Of Supply Chain And Facility Operations | Leadership |
Vernon Atkinson | Senior Director, Operations, ADMA BioCenters | Leadership |
Lucy Demario | Senior Director, Scientific & Data Analysis | Leadership |
Michael Goldstein | Executive Director, General Counsel | Leadership |
Jeffrey Janek | VP, Production Operations | Leadership |
Skyler Bloom | Senior Director, Business Development & Corporate Strategy | Leadership |
Cindy Petersen | Executive Director, Human Resources | Leadership |
Ricardo Carneiro | Senior Director, Market Access & Reimbursement | Leadership |
James Maloney | Senior Director, Regulatory Affairs | Leadership |
Adam S. Grossman | Founder, Director, President & CEO | Leadership |
Brad Tade | Chief Financial Officer And Treasurer | Leadership |
Robert Brooks | Senior Director, Data Integrity & IT Operations | Leadership |
Cyril J. | Associate Director, Information Technology Operations | Leadership |
Jennifer Kelley | Associate Director Of HR | Leadership |
Marie-Chantale Simard | Director Medical Affairs | Leadership |
Shane Stremming | VP, Plasma Operations | Leadership |
Frank Sananes | Senior Director, Validation | Leadership |
22 more people are available in the full profile.
Complete people profiles for ADMA Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ADMA Biologics
ADMA Biologics is a publicly listed company on the NASDAQ with ticker symbol ADMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Oct 2013
- Listed onNASDAQ: ADMA
- Listed entityADMA Biologics Inc
- Exchange sectorHealth technology
- ISINUS0008991046
- Share price$10.31 (+1.28% on the day) · 2026-10-13
- Market capitalisation$2.31B
- Price to earnings14.6
- EPS (diluted, trailing year)$0.70
- Volume (last session)3,764,972
Financials of ADMA Biologics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $510.2M | $146.9M | $199.5M |
| 2024 | $426.4M | $197.7M | $147.0M |
| 2023 | $258.2M | -$28.2M | $30.0M |
| 2022 | $154.1M | -$65.9M | -$32.5M |
| 2021 | $80.9M | -$71.7M | -$53.1M |
Detailed financial statements for ADMA Biologics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ADMA Biologics
4 dated milestones of ADMA Biologics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded ADMA Biologics is founded.
- Funding First funding round of $17.6M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Conventional, of $72.5M.
Competitors of ADMA Biologics
ADMA Biologics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Kymeratx and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of ADMA Biologics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ADMA Biologics
The website of ADMA Biologics (admabiologics.com) receives about 12.7K visits a month.
- Monthly visits12.7K
▼ 17.2% vs previous month
Websites whose visitors overlap most with ADMA Biologics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| therapeuticsmd.com | 100% | 3.4K | #3,477,902 | View details | |
news.stocktradersdaily.com | news.stocktradersdaily.com | 97% | #474,824 | – | |
| blackhawknetwork.com | 66% | 2.4M | #25,342 | View details | |
bbt.com | bbt.com | 59% | #369,371 | – | |
| marketwatch.com | 40% | 34.7M | #2,123 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for ADMA Biologics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as ADMA Biologics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adma Biologics
Complete news archive for ADMA Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ADMA Biologics
ADMA Biologics was founded in 2005 and raised its 1st funding round 7 years after it was founded.
ADMA Biologics is headquartered in Ramsey, United States. It is registered at Ramsey, Minnesota, United States.
Adam Grossman is the CEO of ADMA Biologics, as recorded in our data. They have also founded this company.
ADMA Biologics is a funded company, having raised a total of $17.55M across 6 funding rounds to date. The company's 1st funding round was a Private Equity Round of $17.55M, raised on Feb 2012.
ADMA Biologics has 685 employees.
Annual revenue of ADMA Biologics is $510.17M as on Dec 31, 2025.
ADMA Biologics was founded in 2005 and is headquartered in Ramsey, United States. Operations focus on the development, manufacturing, and marketing of plasma-derived immune globulins targeted at niche patient populations. These biologics address primary immune deficiency diseases and certain infectious conditions. The lead product, RI-002, completed phase 3 clinical trials, with a biologics license application submitted to the FDA in 2015.
ADMA Biologics's top competitors include Kymeratx, PureTech Health and Biogen.
ADMA Biologics offers ASCENIV, BIVIGAM, and Nabi-HB.
Yes, ADMA Biologics is publicly traded on NASDAQ under the ticker symbol ADMA.
ADMA Biologics has 5 investors. Key investors include Hercules Capital, Oxford Finance, Perceptive Advisors, Burrill and Company, and Aisling Capital.
ADMA Biologics operates through Adma Biologics, Inc..